July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Efficacy and Safety of Riboflavin-Ultraviolet Type A Rays Inducing Cross-Linking of Corneal Collagen in Patients Aged 8 to 16 Years with Progressing Keratoconus
Author Affiliations & Notes
  • Julia Polido
    Ophthalmology, UNIFESP, Vitória, ES, Brazil
  • Maria Emília Araújo
    Ophthalmology, UNIFESP, Vitória, ES, Brazil
  • Eliane Nakano
    Ophthalmology, UNIFESP, Vitória, ES, Brazil
  • Taís Wakamatsu
    Ophthalmology, UNIFESP, Vitória, ES, Brazil
  • Luiz Guilherme Mello
    Ophthalmology, UFES, Vitória, ES, Brazil
  • Thiago Cabral
    Ophthalmology, UNIFESP, Vitória, ES, Brazil
    Ophthalmology, UFES, Vitória, ES, Brazil
  • Denise Freitas
    Ophthalmology, UNIFESP, Vitória, ES, Brazil
  • Footnotes
    Commercial Relationships   Julia Polido, None; Maria Emília Araújo, None; Eliane Nakano, None; Taís Wakamatsu, None; Luiz Guilherme Mello, None; Thiago Cabral, None; Denise Freitas, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5759. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Julia Polido, Maria Emília Araújo, Eliane Nakano, Taís Wakamatsu, Luiz Guilherme Mello, Thiago Cabral, Denise Freitas; Efficacy and Safety of Riboflavin-Ultraviolet Type A Rays Inducing Cross-Linking of Corneal Collagen in Patients Aged 8 to 16 Years with Progressing Keratoconus. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5759.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the effectiveness and safety of riboflavin–ultraviolet type A (UVA) rays induced cross-linking (CXL) of corneal collagen in reducing progression of keratoconus and in improving visual acuity in pediatric patients with progressive keratoconus

Methods : Prospective nonrandomized open study comprised 58 eyes of 58 patients, aged between 8 to 16 years affected by documented progressive keratoconus, were treated by combined riboflavin–UVA rays collagen CXL. Radiant energy was 3 mW/cm2 or 5.4 joule/cm2 for a 30-minute exposure at 5 cm from the corneal apex. A complete ophthalmologic examination (uncorrected visual acuity [UCVA], best spectacle-corrected visual acuity [BSCVA]) was performed before treatment, at 3 months, 6 months, 1, 2 and 3 to 4 years afterwards. Patients had corneal topography, anterior segment ocular coherence tomography and Scheimpflug imaging

Results : The mean age was 12.5 ± 1.9 years, 46 males. Ocular allergy was presented in 86.2% and family history of keratoconus in 31.0%. UCVA and BSCVA improvements were statistically significant (P<0.001) throughout the entire postoperative period (Figure 1). Mean ± SE baseline flattest keratometry (K1), steepest keratometry (K2), average keratometry and maximum keratometry were 47.95 ± 0.60 D, 53.29 ± 0.74 D, 50.42 ± 0.65 D and 60.16 ± 1.02 D respectively. At 3 to 4 years, these readings were 47.03 ± 0.63 D, 51.70 ± 0.76 D, 49.24 ± 0.66 D and 58.25 ± 1.05 D respectively, all statistically significant. Topographic corneal astigmatism showed reduction at 1 year after CXL, being similar at 2 and 3 to 4 years (p<0,001). There was a decrease in thinnest pachymetry in both exams, Visante OCT and Pentacam HR, between baseline and 3 months after CXL (mean change 21.45 mm, p<0,001). The variation in thinnest pachymetry between 3 months and 1, 2 and 3 to 4 years was not statistically significant and the mean thinnest pachymetry remained decreased from baseline (Table 1). Corneal haze was the main complication, presented in 50% at 3 months, remained similar at 6 months and 1 year, and decreased at 2 years (p<0,001).

Conclusions : Cross-linking showed to be safe and effective in pediatric patients in 3-4 years follow-up. A good functional response in visual acuity and keratoconus stability was obtained after corneal CXL during this period.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×